Bioventus (BVS) Cost of Revenue (2020 - 2026)

Bioventus' Cost of Revenue history runs 7 years deep, the most recent figure standing at $41.3 million for Q1 2026.

• Quarterly Cost of Revenue rose 1.22% year-over-year to $41.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $180.4 million (down 2.36% YoY) and the FY2025 annual result came in at $179.9 million, down 2.77% from the prior year.
• Cost of Revenue was $41.3 million for Q1 2026 at Bioventus, down from $49.1 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $51.6 million in Q4 2022 and bottomed at $40.8 million in Q1 2025.
• A 5-year average of $45.4 million and a median of $45.1 million in 2023 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2022 — Cost of Revenue jumped 87.15% — and 2024, when it slipped 9.0%.
• Bioventus' Cost of Revenue stood at $51.6 million in 2022, then decreased by 4.89% to $49.1 million in 2023, then grew by 3.79% to $51.0 million in 2024, then fell by 3.66% to $49.1 million in 2025, then declined by 15.88% to $41.3 million in 2026.
• Business Quant data shows BVS's Cost of Revenue at $41.3 million in Q1 2026, $49.1 million in Q4 2025, and $44.4 million in Q3 2025.